The Evolving Use of Gemtuzumab Ozogamicin in Acute Myeloid Leukemia

被引：0
|
作者：
Walter, Roland B. [1 ,2 ,3 ,4 ]
机构：
[1] Univ Washington, Fred Hutchinson Canc Res Ctr, Sch Med, Div Clin Res, Seattle, WA 98195 USA
[2] Univ Washington, Sch Med, Div Hematol, Med, Seattle, WA 98195 USA
[3] Univ Washington, Sch Med, Dept Lab Med & Pathol, Seattle, WA 98195 USA
[4] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：152 / 154
页数：3
相关论文
共 50 条
  • [41] Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia
    Hibma, Jennifer
    Knight, Beverly
    CLINICAL PHARMACOKINETICS, 2019, 58 (03) : 335 - 347
  • [42] Spotlight on Gemtuzumab Ozogamicin in Acute Myeloid Leukaemia
    Caroline Fenton
    Caroline M. Perry
    BioDrugs, 2006, 20 : 137 - 139
  • [43] Spotlight on gemtuzumab ozogamicin in acute myeloid leukaemia
    Fenton, Caroline
    Perry, Carolbie M.
    BIODRUGS, 2006, 20 (02) : 137 - 139
  • [44] Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia
    Mort, Joseph F.
    Brighton, David
    Dibenedetto, Samantha
    Wells, Leah
    Clark, Stephen M.
    Reid, Justin
    Patel, Imari
    Jackson, Clayton
    Yelvington, Bradley
    Miller, Ryan
    Perciavalle, Matthew
    Walsh, Katherine
    Wolfe, Heather
    Locke, Susan C.
    Zeidner, Joshua F.
    Duong, Vu H.
    Reed, Daniel R.
    Dholaria, Bhagirathbhai
    Leblanc, Thomas W.
    Keng, Michael
    Horton, Bethany
    El Chaer, Firas
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (03) : 481 - 494
  • [45] Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia
    El Kinge, Abdul Rahman
    Hatourn, Hassan A.
    Mahfouz, Rami A.
    Otrock, Zaher K.
    Jabbour, Elias
    Kantarjian, Hagop
    Bazarbachi, Ali
    LEUKEMIA RESEARCH, 2009, 33 (04) : 565 - 566
  • [46] Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia
    Chantepie, Sylvain P.
    Reboursiere, Emilie
    Mear, Jean-Baptiste
    Gac, Anne-Claire
    Salaun, Veronique
    Benabed, Khaled
    Cheze, Stephane
    Johnsonansah, Hyacinthe
    Macro, Margaret
    Vilque, Jean-Pierre
    Reman, Oumedaly
    LEUKEMIA & LYMPHOMA, 2015, 56 (08) : 2326 - 2330
  • [47] Distinct Signaling Profiles of Gemtuzumab Ozogamicin Responsiveness and Refractoriness in Acute Myeloid Leukemia
    Rosen, David B.
    Cordeiro, James A.
    Soper, David M.
    Huang, Ying-Wen
    Hogge, Donna E.
    Walter, Roland B.
    Cesano, Alessandra
    Fantl, Wendy J.
    BLOOD, 2009, 114 (22) : 1073 - 1074
  • [48] Trials with gemtuzumab ozogamicin (Mylotarg®) combined with chemotherapy regimens in acute myeloid leukemia
    Stadtmauer, EA
    CLINICAL LYMPHOMA, 2002, 2 : S24 - S28
  • [49] Gemtuzumab ozogamicin in the treatment of critically ill patients with refractory acute myeloid leukemia
    Zaytsev, D.
    Girshova, L.
    Ivanov, V.
    Budaeva, I.
    Motorin, D.
    Badaev, R.
    Bogdanov, K.
    Mirolubova, J.
    Nikulina, T.
    Chitanava, T.
    Alexeeva, J.
    Zaritskey, A.
    LEUKEMIA RESEARCH, 2019, 85 : S65 - S66
  • [50] Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
    Duong, Hien K.
    Sekeres, Mikkael A.
    CLINICAL INTERVENTIONS IN AGING, 2009, 4 : 197 - 205
12345